LIMITATIONS OF THE TEST
1. To enhance sensitivity and specificity of this IgM test provided sample diluent has been formulated to block IgG and Rheumatoid Factor (RF) interferences. Turbidity could be seen after diluting serum with sample diluent. This turbidity is due to the blocking of serum IgG and has shown no interference with test results. It can be removed by centrifugation.
2. In specimens with high RF and high autoimmune antibodies, the possibility of eliminating the interferences cannot be ruled out entirely.
3. Lipemic or hemolyzed samples may cause erroneous results.

REFERENCES

SUMMARY AND EXPLANATION
Treponema pallidum is the causative agent of syphilis, a contagious and infectious systemic disease characterized by periods of active florid manifestations and by years of symptomless latency. Syphilis is traditionally classified as acquired or congenital, each being further subdivided on the basis of the natural course of the disease. In acquired syphilis, infection is usually transmitted by sexual intercourse. The incubation period of syphilis can vary from 1 to 13 weeks, but usually from 3 - 4 weeks. Untreated patients with primary or secondary syphilis having active lesions are the most infectious, and the risks of contagion are greatest during the first 2 years of infection. Virtually every organ and tissue of the body is affected, including most body fluids. Over 80% of patients have mucocutaneous lesions, 50% have generalized enlargement of the lymph nodes, and about 10% have lesions of the eyes, bones and joints, meninges, liver, and spleen. Mild constitutional symptoms of malaise, headache, anorexia, nausea, aching pains in the bones, and fatigability are often present. Congenital syphilis is the result of passage of T. pallidum across the placenta. Clinical manifestations may be present at birth but are more often seen at 3 weeks to 6 months of age. Two types of antibodies are produced by T. pallidum: nontreponemal antibodies (reagin) and treponemal antibodies. ELISA for detection of IgG and IgM antibodies is becoming the Gold standard for the diagnosis of syphilis.

PRINCIPLE OF THE TEST
Diluted patient serum (serum diluent contains sorbent to remove Rheumatoid Factor and human IgG interference) is added to wells coated with purified antigen. IgM specific antibody, if present, binds to the antigen. All bound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgM specific antibody in the sample.

MATERIALS PROVIDED

<table>
<thead>
<tr>
<th>Material</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microwells coated with T. pallidum antigen</td>
<td>12x8x1</td>
</tr>
<tr>
<td>Sample Diluent: 1 bottle (ready to use)</td>
<td>22 ml</td>
</tr>
<tr>
<td>Calibrator: 1 Vial (ready to use)</td>
<td>1 ml</td>
</tr>
<tr>
<td>Positive Control: 1 vial (ready to use)</td>
<td>1 ml</td>
</tr>
<tr>
<td>Negative Control: 1 vial (ready to use)</td>
<td>1 ml</td>
</tr>
<tr>
<td>Enzyme conjugate: 1 bottle (ready to use)</td>
<td>12 ml</td>
</tr>
<tr>
<td>TMB Substrate: 1 bottle (ready to use)</td>
<td>12 ml</td>
</tr>
<tr>
<td>Stop Solution: 1 bottle (ready to use)</td>
<td>12 ml</td>
</tr>
<tr>
<td>Wash concentrate 20X: 1 bottle</td>
<td>25 ml</td>
</tr>
</tbody>
</table>

For Order and Inquiries, please contact
Calbiotech Inc.,
10461 Austin Dr, Spring Valley, CA, 91978
Tel (619) 660-6162, Fax (619) 660-6970,
www.calbiotech.com
MATERIALS NOT PROVIDED
1. Distilled or deionized water
2. Precision pipettes, Disposable pipette tips
3. ELISA reader capable of reading absorbance at 450nm
4. Absorbance paper or paper towel
5. Graph paper

STORAGE AND STABILITY
1. Store the kit at 2-8°C.
2. Keep microwells sealed in a dry bag with desiccants.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light.

WARNINGS AND PRECAUTIONS
1. Potential biohazardous materials:
   The calibrator and controls contain human source components which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent. These reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health manual, “Biosafety in Microbiological and Biomedical Laboratories” 1984.
2. This kit is designed for research use only.
3. Optimal results will be obtained by strict adherence to the test protocol. Precise pipetting as well as following the exact time and temperature requirements is essential.
4. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
5. The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed.
6. Control sera and sample diluent contain preserved with sodium azide. Sodium azide may react with lead and copper plumbing to form explosive metal azide. On disposal, flush with a large volume of water.

SPECIMEN COLLECTION AND HANDLING
1. Collect blood specimens and separate the serum.
2. Specimens may be refrigerated at 2–8°C for up to seven days or frozen for up to six months. Avoid repetitive freezing and thawing.

REAGENT PREPARATION
Prepare 1X Wash buffer by adding the contents of the bottle (25 ml, 20X) to 475 ml of distilled or deionized water. Store at room temperature (18-26°C).

ASSAY PROCEDURE
Bring all specimens and kit reagents to room temperature (18-26°C) and gently mix.
1. Place the desired number of coated strips into the holder.
2. Negative control, positive control, and calibrator are ready to use. Prepare 1:21 dilution of test samples, by adding 10 µl of the sample to 200 µl of sample diluent. Mix well.
3. Dispense 100 µl of diluted sera, calibrator and controls into the appropriate wells. For the reagent blank, dispense 100µl sample diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 20 minutes at room temperature.
4. Remove liquid from all wells. Wash wells three times with 300 µl of 1X wash buffer. Blot on absorbance paper or paper towel.
5. Dispense 100 µl of enzyme conjugate to each well and incubate for 20 minutes at room temperature.
6. Remove enzyme conjugate from all wells. Wash wells three times with 300 µl of 1X wash buffer. Blot on absorbance paper or paper towel.
7. Dispense 100 µl of TMB substrate and incubate for 10 minutes at room temperature.
8. Add 100 µl of stop solution.
9. Read O.D. at 450 nm using ELISA reader within 15 min. A dual wavelength is recommended with reference filter of 600-650 nm.

CALCULATION OF RESULTS
1. Check Calibrator Factor (CF) value on the calibrator bottle. This value might vary from lot to lot. Make sure you check the value on every kit.
2. Calculate the cut-off value: Calibrator OD x Calibrator Factor (CF).
3. Calculate the Ab (Antibody) Index of each determination by dividing the O.D. value of each sample by cut-off value.

Example of typical results:
Calibrator mean OD = 0.8
Calibrator Factor (CF) = 0.5
Cut-off Value = 0.8 x 0.5= 0.400
Positive control O.D. = 1.2
Ab Index = 1.2 / 0.4 = 3
Patient sample O.D. = 1.6
Ab Index = 1.6 / 0.4 = 4.0

QUALITY CONTROL
The test run may be considered valid provided the following criteria are met:
1. The O.D. of the Calibrator should be greater than 0.250.
2. The Ab index for Negative control should be less than 0.9.
3. The Ab Index for Positive control should be greater than 1.2.

INTERPRETATION
The following is intended as a guide to interpretation of Treponema pallidum IgM test results; each laboratory is encouraged to establish its own criteria for test interpretation based on sample populations encountered.

Antibody Index Interpretation
<0.9 No detectable antibody to Treponema pallidum IgM by ELISA.
0.9-1.1 Borderline positive. Follow-up testing is recommended if clinically indicated.
>1.1 Detectable antibody to Treponema pallidum IgM by ELISA.